Summary

Although coronary artery disease accounts for 75% of deaths in patients with diabetes, few studies have compared antidiabetic agents beyond their glucose-lowering efficacy. The prospective, randomized PERISCOPE trialtrial showed that an insulin-sensitizing drug (pioglitazone) may be more effective than a traditional insulin secretagogue (glimepiride) in stopping or reducing the progression of atherosclerosis.